Cipemastat is primarily investigated for its potential therapeutic applications in conditions involving excessive tissue degradation, such as arthritis and cancer. It functions as a selective inhibitor of matrix metalloproteinases (MMPs), enzymes that play a critical role in breaking down extracellular matrix components. By inhibiting these enzymes, cipemastat can help reduce tissue destruction and inflammation, making it a promising candidate for treating diseases like rheumatoid arthritis and osteoarthritis. Additionally, its ability to modulate MMP activity has sparked interest in its use for controlling tumor progression and metastasis in certain cancers, as MMPs are often overexpressed in malignant tissues. Research continues to explore its efficacy and safety in these clinical contexts.